Literature DB >> 29715104

Hypermethylation of BRCA1 Gene in Meningioma in Elderly Males.

Ismael Augusto Silva Lombardi1,2, Mário Henrique Girão Faria3, Silvia Helena Barem Rabenhorst4, Marco Antônio Zanini2, Maria Inês DE Moura Campos Pardini1,5, Rejane Maria Tommasini Grotto1,6, Adriana Camargo Ferrasi7,5.   

Abstract

BACKGROUND/AIM: Breast cancer 1, early onset (BRCA1) gene is expressed in the cells of the breast and other tissues, where it plays a role in cell-cycle regulation, transcription, repair of DNA double-stranded breaks, ubiquitination, transcriptional regulation as well as other functions, such as cell response regulation to mitogenic signals triggered by estrogens. Considering that meningioma shows greater tumor growth during pregnancy, can express estrogen receptors and proliferate in response to estrogenic stimulation, the hypothesis that this type of tumor may share molecular mechanisms that involve exposure to estrogen should be investigated. Therefore, the aim of the present study was to investigate the BRCA1 gene methylation profile in meningioma.
MATERIALS AND METHODS: Methylation-specific polymerase chain reaction (PCR) assay was performed on 50 meningioma samples from male and female patients. Statistical analysis was carried out using Fisher's exact test.
RESULTS: The most important finding of this study was that 100% of the male patients over 55 years with meningioma showed BRCA1 methylated in their tumor cells.
CONCLUSION: The silencing of BRCA1 through hypermethylation seems to play an important role in meningioma. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  BRCA1; elderly males; estrogens; hypermethylation; meningioma

Mesh:

Substances:

Year:  2018        PMID: 29715104     DOI: 10.21873/anticanres.12526

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Past medical history of tumors other than meningioma is a negative prognostic factor for tumor recurrence in meningiomas WHO grade I.

Authors:  Annamaria Biczok; Philipp Karschnia; Raffaela Vitalini; Markus Lenski; Tobias Greve; Jun Thorsteinsdottir; Rupert Egensperger; Franziska Dorn; Jörg-Christian Tonn; Christian Schichor
Journal:  Acta Neurochir (Wien)       Date:  2021-03-05       Impact factor: 2.216

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.